In the post-neoadjuvant setting, the KATHERINE trial should be mentioned: administration of T-DM1 (compared to trastuzumab) to patients with HER2pos BC showing residual disease at surgery following standard NACT and single or dual HER2-blockade revealed a striking 11% absolute improvement in IDFS. Here, ERBB2 is linked to breast cancer.